EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transcription factor TCF7L1 targeting HSPB6 is involved in EMT and PI3K/AKT/mTOR pathways in bladder cancer

Zizhi Li, Junyi Li, Qingfei Cao, Tong Shen, Yingjie Wang, Haoyang He, Ming Tong

Journal of Biological Chemistry · 2025

DOI: 10.1016/j.jbc.2024.108024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Zizhi Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Soochow University, Soochow, Jiangsu, China; Department of Urology, The First Affiliated Hospital of Jinzhou Medical Universi…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bladder cancer is notorious for its high recurrence and costly treatment burden, prompting a search for novel therapeutic targets. Our study focuses on HSPB6, a small heat shock protein whose reduced expression in bladder cancer suggests a role in tumor biology. Using an integrative approach of bioinformatics, RNA sequencing, and cell-based assays, we show that HSPB6 upregulation inhibits cancer cell proliferation and metastasis while promoting apoptosis. Moreover, TCF7L1-mediated upregulation of HSPB6 leads to suppression of the PI3K/AKT/mTOR signaling pathway, a key driver of cancer progression. These results position HSPB6 as a compelling target for bladder cancer therapy, and its regulatory role in the PI3K/AKT/mTOR axis underscores its therapeutic potential. Our findings pave the way for future investigations into HSPB6-centered treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesSignal TransductionEpithelial-Mesenchymal TransitionHumansCell Line, TumorCell ProliferationAnimalsGene Expression Regulation, NeoplasticMiceApoptosis

Stichwörter der Autor:innen

EMTPI3K/AKT/mTORbladder cancerheat shock protein B6progressiontranscription factor 7-like 1

Substanzen

TOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesMTOR protein, human

Autor:innen und Institutionen

  • Department of Medicine, Soochow University, Soochow, Jiangsu, China; Department of Urology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
  • Department of Urology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
  • Department of Medicine, Soochow University, Soochow, Jiangsu, China; Department of Urology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China. Electronic address: tongming_mail@163.co…

Zitieren

APA

Li, Z., Li, J., Cao, Q., Shen, T., Wang, Y., He, H., & Tong, M. (2025). Transcription factor TCF7L1 targeting HSPB6 is involved in EMT and PI3K/AKT/mTOR pathways in bladder cancer. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2024.108024

Vancouver

Li Z, Li J, Cao Q, Shen T, Wang Y, He H, et al. Transcription factor TCF7L1 targeting HSPB6 is involved in EMT and PI3K/AKT/mTOR pathways in bladder cancer. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2024.108024

BibTeX
@article{Li2025,
  author = {Li, Zizhi and Li, Junyi and Cao, Qingfei and Shen, Tong and Wang, Yingjie and He, Haoyang and Tong, Ming},
  title = {Transcription factor TCF7L1 targeting HSPB6 is involved in EMT and PI3K/AKT/mTOR pathways in bladder cancer},
  journal = {Journal of Biological Chemistry},
  year = {2025},
  doi = {10.1016/j.jbc.2024.108024}
}
Kostenlos starten →